Top Ten most popular articles on Pharmafile.com this week
It's been a busy week on Pharmafile.com over the last seven days. Europe's first biosimilar treatment for cancer continues to resonate throughout the industry, and the week was marked by the shock departure of a number of pharma executives. Also proving popular was our feature on Trump's blusterous first month taking on big pharma - but what threat does he pose to the future of the FDA?
Check out the Top Ten most popular articles on Pharmafile.com this week!
Ocaliva has been approved by NICE for the treatment of the chronic liver disease primary biliary cholangitis (PBC).
Cuba once again leads the way with HIV treatment by beginning a trial on a vaccine that would reduce the levels of the virus in the blood without toxic side-effects.
Research shows that use of weight loss drug liraglutide lowers the risk of developing type 2 diabetes by 80% versus placebo.
Medication that is used to treat those suffering from weakened bones may actually be causing further damage, new research from scientists at Imperial College London has found.
MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by NICE for the treatment of untreated PD-L1-positive metastatic lung cancer.
The first biosimilar will be made available in Europe to match the indications of Roche’s best-selling cancer drug, Rituxan.
Executive Vice President, Head of North American Operations Jakob Riis has resigned from the company, and will be replaced by current Senior Vice President for Market Access Doug Langa.
President Trump's pledge to slash regulation in the pharma sector by 75% has already drawn concern from industry figures; what effects could his executive orders and overall plan have on the future of the United States' drug regulatory body?
A death in Roche's trial for its haemophilia medication, emicizumab, is expected to dent confidence in the drug's safety profile.
AstraZeneca has announced that its type-2 diabetes treatment Qtern (10mg dapagliflozin and 5mg saxagliptin) has received the approval of the US Food and Drug Administration.